Stereotactic irradiation of GH-secreting pituitary adenomas

G. Minniti, C. Scaringi, D. Amelio, R. Maurizi Enrici

Research output: Contribution to journalArticlepeer-review


Radiotherapy (RT) is often employed in patients with acromegaly refractory to medical and/or surgical interventions in order to prevent tumour regrowth and normalize elevated GH and IGF-I levels. It achieves tumour control and hormone normalization up to 90 and 70 of patients at 10-15 years. Despite the excellent tumour control, conventional RT is associated with a potential risk of developing late toxicity, especially hypopituitarism, and its role in the management of patients with GH-secreting pituitary adenomas remains a matter of debate. Stereotactic techniques have been developed with the aim to deliver more localized irradiation and minimize the long-term consequences of treatment, while improving its efficacy. Stereotactic irradiation can be given in a single dose as stereotactic radiosurgery (SRS) or in multiple doses as fractionated stereotactic radiotherapy (FSRT). We have reviewed the recent published literature on stereotactic techniques for GH-secreting pituitary tumors with the aim to define the efficacy and potential adverse effects of each of these techniques.

Original languageEnglish
Article number482861
JournalInternational Journal of Endocrinology
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Stereotactic irradiation of GH-secreting pituitary adenomas'. Together they form a unique fingerprint.

Cite this